As Medical Imaging Prices Fall, Market Turns to Developing Regions, Nontraditional Applications, Ultrasound, and Contrast Agents for Opportunities
FARMINGTON, Conn., Sept. 24, 2012 /PRNewswire-iReach/ — As the medical imaging industry approaches maturity in developed markets, imaging machine makers such as GE and Siemens AG are looking to bolster significant growth in the developing markets. Nontraditional uses for diagnostics and monitoring for both new therapies and minimally invasive procedures is expected to drive growth in the U.S., reports The Wall Street Journal. The market for contrast agents and radiopharmaceuticals is also expected to sustain decent growth in the next few years, with much of that growth coming from the MRI, ultrasound and nuclear medicine modalities. For example, specific advances in contrast agent-enabled diagnostics mammography and Alzheimer’s will provide new interesting opportunities in the field.
Detailed reports available from Global Information Inc. reveal the global imaging market scenario, the potential for bottlenecks in developing markets, revenue forecasts, procedure volumes, and more.
Medical Imaging Markets: Contrast Agents
While equipment manufacturers may have experienced a slump in sales due to the recent recession, there is still a need for contrast agents, as well as for radiopharmaceuticals, to help image, track and diagnose disease, especially in the elderly. Even though hospitals and clinics may have slowed their equipment purchases because of the need to contain costs, procedures run on installed systems still require the use of contrast agents and radiopharmaceuticals.
The report provides world and regional revenue forecasts for contrast agents and radiopharmaceuticals by modality through 2016; covers market share of major contrast agent suppliers and procedure volumes by modality and region; includes estimates of the portion of procedures in each modality using contrast enhancement; and details contrast-enhancement products in development.
An executive summary and free sample pages from the full study are available at http://www.giiresearch.com/report/kl102354-med-image-contr.html
The dynamics of imaging agents are changing and significant growth lies ahead. Among the key trends: ultrasound contrast media is a rising star in the quadrant; PET is a prime growth driver for radiopharmaceuticals; nuclear medicine provides a potential growth avenue for radiopharmaceuticals; and fledging market battles teething challenges.
This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following Product Segments: Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 55 companies including many key and niche players such as AMAG Pharmaceuticals Inc., Bayer Schering Pharma AG, Bracco Group, Covidien, Daiichi Sankyo Company Limited, Eisai Co., Ltd, EUSA Pharma, Inc., GE Healthcare, Guerbet Group, and Lantheus Medical Imaging.
An executive summary and free sample pages from the full study are available at http://www.giiresearch.com/report/go236838-imaging-agents.html
European Contrast Media and Radiopharmaceuticals Market
This research service aims to provide a detailed analysis of the contrast media and radiopharmaceuticals market in European nations, focusing on the United Kingdom, Germany, France, Italy, Spain, and Benelux and Scandinavian countries. This research service includes a brief market overview of contrast media and radiopharmaceuticals, the transport mechanisms for radiopharmaceuticals, analysis of the challenges affecting the industry, factors driving and restraining the growth of the market, and the revenue forecasts. The main objectives of this study are to provide an understanding of market opportunities, market size, and forecast assessment.
An executive summary and free sample pages from the full study are available at http://www.giiresearch.com/report/fs244856-european-contrast-media-radiopharmaceuticals.html
This report analyzes the US and the European markets for Radiopharmaceuticals in US$ Million by the following Product Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 65 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Bio-Nucleonics, Inc., Bracco Diagnostics, Inc., Cardinal Health, Inc., Cellectar, LLC., Cell Therapeutics, Inc., Covidien Imaging Solutions, EUSA Pharma (Europe) Ltd., Jubilant DraxImage Inc., GE Healthcare Limited, GlaxoSmithKline Plc, IBA Group, Immunomedics, Inc., Lantheus Medical Imaging, Inc, Nordion, Molecular Insight Pharmaceuticals, Inc., Novelos Therapeutics Inc., Peregrine Pharmaceuticals, Inc., PETNET Pharmaceuticals, Inc., Pharmalucence, Inc., Spectrum Pharmaceuticals, Inc., and Triad Isotopes, Inc.
An executive summary and free sample pages from the full study are available at http://www.giiresearch.com/report/go225236-radiopharmaceuticals.html
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.
Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Global Information, Inc.